Journal of Breast Cancer最新文献

{"title":"Isolated Regional Nodal Recurrence After Primary Breast Cancer: Risk Factors and Survival by Mode of Detection.","authors":"Myoung Kyoung Kim, Seok Won Kim, Joong Hyun Ahn, Haejung Kim, Ji Soo Choi, Eun Young Ko, Boo-Kyung Han, Jonghan Yu, Eun Sook Ko","doi":"10.4048/jbc.2026.0009","DOIUrl":"10.4048/jbc.2026.0009","url":null,"abstract":"<p><strong>Purpose: </strong>The prognostic relevance of the detection mode for regional lymph node recurrence (LNR) remains unclear. We aimed to identify the risk factors associated with isolated regional LNR and to evaluate the impact of the mode of detection on distant metastasis-free survival (DMFS) and overall survival (OS).</p><p><strong>Methods: </strong>This retrospective cohort study included women who underwent surgery for stage I-III invasive breast cancer between January 2011 and December 2019, with follow-up until December 2024. Isolated regional LNR was categorized according to the detection method (imaging vs. symptoms). Risk factors were identified using the Fine-Gray sub-distribution hazard model, and DMFS and OS were compared using Kaplan-Meier analysis and log-rank tests.</p><p><strong>Results: </strong>Among 13,406 women (median age, 49 years; range, 20-87 years), 126 (0.9%) developed isolated regional LNR during a median follow-up of 6.3 years. Of these, 118 (93.7%) were detected through imaging and 8 (6.3%) through symptoms. Independent risk factors for isolated regional LNR included higher T stages (T2: hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.11-2.64; T3: HR, 3.08; 95% CI, 1.68-5.65), higher N stages (N2: HR, 2.97; 95% CI, 1.54-5.75; N3: HR, 3.12; 95% CI, 1.36-7.13), triple-negative subtype (HR, 1.71; 95% CI, 1.09-2.67), and omission of adjuvant radiotherapy (HR, 4.35; 95% CI, 2.86-6.67). Radiological patterns varied by detection, with ultrasound usually detecting level I nodes (51.6%) and computed tomography detecting internal mammary nodes (58.1%). Symptom-detected recurrence frequently occurred in the supraclavicular region (50.0%). Symptom-detected LNRs were associated with significantly worse DMFS (<i>p</i> < 0.05) than imaging-detected LNRs; however, OS did not differ between the groups.</p><p><strong>Conclusion: </strong>The detection mode was associated with DMFS, but not OS, suggesting that long-term outcomes are driven more by disease biology than by how recurrence is detected.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"339-353"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting Highlights: The 11th Korean Breast Cancer Society Consensus Conference on Axillary Management in Early Breast Cancer.","authors":"Soong June Bae, Jun-Hee Lee, Seung Ah Lee, Hye Sung Won, Han Jo Kim, Heejung Chae, Kabsoo Shin, Ji Hyung Hong, Yoon Jin Cha, Hee Kyung Ahn, Airi Han, Sang-Ah Han","doi":"10.4048/jbc.2026.0144","DOIUrl":"10.4048/jbc.2026.0144","url":null,"abstract":"<p><p>The 11th Korean Breast Cancer Society (KBCS) Consensus Meeting was convened to discuss the current expert opinions and practice patterns regarding controversial issues in the axillary management of early breast cancer in Korea. Fifty-three multidisciplinary experts participated in the panel voting. The case-based questions addressed three major domains: 1) omission of sentinel lymph node biopsy (SLNB) in clinically node-negative disease, 2) management of sentinel lymph node (SLN) micrometastases after upfront surgery, and 3) axillary management after neoadjuvant chemotherapy (NAC) for biopsy-proven node-positive disease. The panelists showed a cautious attitude toward SLNB omission in relatively younger postmenopausal patients, even when the clinicopathologic features were consistent with contemporary de-escalation trials, whereas support for omission increased substantially in older low-risk patients. For SLN micrometastases after upfront surgery, completion of axillary lymph node dissection (ALND) is rarely supported, although opinions vary regarding the need for axillary radiotherapy. In the neoadjuvant setting, routine clip placement in biopsy-proven positive nodes has not yet been universally adopted. However, there is strong support for omitting ALND in patients who convert to a clinically node-negative status with negative SLNs after NAC. The management of residual nodal disease after NAC remains controversial, particularly in cases of residual macrometastasis. The 11th KBCS Consensus Meeting demonstrated broad acceptance of axillary surgical de-escalation in selected clinical scenarios, while highlighting a persistently uncertain area. These findings emphasize the need for individualized, multidisciplinary decision-making and further prospective evidence to refine the axillary management of early breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"29 4","pages":"313-323"},"PeriodicalIF":3.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary Fibrous Tumors of the Breast: Report of Two Cases and Systematic Review.","authors":"Billy Ho Hung Cheung, Sha Zhao, Ava Kwong, Maximus Yeung","doi":"10.4048/jbc.2025.0077","DOIUrl":"10.4048/jbc.2025.0077","url":null,"abstract":"<p><strong>Purpose: </strong>Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms most commonly found in the pleura, but may also arise in other locations. Breast SFTs are extremely rare and infrequently reported. Descriptive data on the clinical, radiological, and pathological characteristics of breast SFTs are important for improving understanding of the disease, treatment strategies, and follow-up planning.</p><p><strong>Methods: </strong>The pathology databases of major surgical centers in Hong Kong, covering January 2020 to June 2023, were assessed to identify cases with a diagnostic code for SFT. A systematic literature search was conducted to identify all reported cases of breast SFTs. The search was performed using multiple scientific databases, including PubMed, Web of Science, Embase, and Scopus.</p><p><strong>Results: </strong>We report two cases of breast SFTs in Chinese female patients without a family history of breast cancer. Both patients presented with a palpable breast lump that appeared suspicious on ultrasonography (Breast Imaging-Reporting and Data System 4). Both patients underwent surgical excision of the lesions with negative margins. The diagnosis of SFT was established based on immunohistochemical findings in tumor samples obtained from surgical excision. No signs of recurrence were observed at follow-up. A literature review yielded 62 cases of breast SFT, including the two cases reported here. No clinically distinguishing features have been reported in the literature, other than that the majority of patients presented with a mass. SFTs were more commonly found in females (n = 47) than in males (n = 15), although the female-to-male ratio was lower than that observed in other breast cancers.</p><p><strong>Conclusion: </strong>We describe two patients with breast SFTs, together with a comprehensive literature review, to contribute to the currently limited knowledge of this disease. A complete picture of the clinical, radiological, and pathological features of breast SFTs could help improve understanding of the condition and guide appropriate management.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"237-247"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Early Breast Cancer: A Comprehensive Review.","authors":"Woong Ki Park, Jai Min Ryu","doi":"10.4048/jbc.2026.0048","DOIUrl":"10.4048/jbc.2026.0048","url":null,"abstract":"<p><p>Hormone receptor-positive (HR+) breast cancer in premenopausal women presents unique therapeutic challenges owing to persistent ovarian estrogen production and aggressive biological features. Although tamoxifen has long been the standard of care, the integration of ovarian function suppression (OFS) has transformed adjuvant management. This review synthesizes landmark clinical trial data, biological rationales, and emerging evidence to guide personalized treatment strategies. The hypothalamic-pituitary-ovarian axis remains the primary source of estrogen in premenopausal women and drives tumor proliferation. Landmark trials, including Suppression of Ovarian Function Trial, Tamoxifen and Exemestane Trial, Addition of Ovarian Suppression to Tamoxifen in Young Women with Hormone-Sensitive Breast Cancer who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy, and Hormonal Bone Effects, have established the superiority of OFS combined with aromatase inhibitors or tamoxifen over tamoxifen monotherapy in high-risk populations. However, the benefits must be weighed against toxicities such as bone loss, menopausal symptoms, and sexual dysfunction. Special subgroups, including young women, patients with invasive lobular carcinoma, and <i>BRCA</i> mutation carriers, derive distinct benefits from OFS. The phenomenon of ovarian escape and the potential of OFS to facilitate chemotherapy de-escalation are emerging as critical considerations. Suppression of ovarian function is the cornerstone of adjuvant therapy for high-risk premenopausal HR+ breast cancers. Optimal management requires a nuanced, risk-stratified approach that balances oncologic efficacy with long-term survivorship, integrating genomic tools and individualized duration strategies.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"29 3","pages":"203-220"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management.","authors":"Jiun-I Lai, Chih-Chiang Hung, Chin-Yao Lin, Chung-Liang Li, Wei-Pang Chung, Ching-Hung Lin, Cheng-Ping Yu, Ming-Yang Wang, Sung-Chao Chu, Chen-Teng Wu, Kuo-Ting Lee, Shyr-Ming Sheen-Chen, Jyh-Cherng Yu, Zhi-Jie Hong, Chao-Ming Hung, Chin-Sheng Hung, King-Jen Chang, Chen-Hsiang Chang, Yuan-Ching Chang, Hsien-Kun Chang, Dwan-Ying Chang, Yao-Jen Chang, Wen-Hung Kuo, Wen-Ling Kuo, Shou-Tung Chen, I-Chun Chen, Fang-Ming Chen, Shin-Cheh Chen, Wei-Wu Chen, Dar-Ren Chen, Ling-Ming Tseng, Yen-Dun Tzeng, Chi-Cheng Huang, Chiun-Sheng Huang, Hsien-Tang Yeh, Guo-Shiou Liao, Ta-Chung Chao, Tsu-Yi Chao, Liang-Chih Liu, Chun-Yu Liu, Ching-Hua Tsai, Fiona Tsui-Fen Cheng, Yen-Shen Lu, Ming-Shen Dai, Chi-Feng Chung, Kun-Ming Rau","doi":"10.4048/jbc.2026.0076","DOIUrl":"10.4048/jbc.2026.0076","url":null,"abstract":"<p><p>Hormone receptor-positive metastatic breast cancer remains a major clinical burden and is characterized by sequential endocrine resistance over the disease course. In 2023, the Taiwan Breast Cancer Society (TBCS) published an expert consensus to support real-world decision-making in Taiwan. Subsequently, rapid advances in biomarker-informed strategies (e.g., estrogen receptor 1 and PI3K/AKT pathway alterations), endocrine partners, estrogen receptor (ER)-targeting agents (including oral selective ER degraders and emerging protein degraders), and the expanding role of antibody-drug conjugates based on human epidermal growth factor receptor 2 expression categories have materially increased the complexity of treatment selection and sequencing. Therefore, TBCS convened an expert panel to update the previous consensus while preserving its foundational framework and eight-chapter structure: risk evaluation and biomarker testing (I/II), first-line treatment selection (I/II), second-line treatment selection (I/II), and treatment options other than endocrine-based approaches (I/II). A multidisciplinary panel conducted a systematic literature review and iterative discussions using a modified Delphi process to identify the key clinical questions, update and refine statements where new evidence was practice-changing, and maintain continuity with the 2023 Consensus. The panel formulated updated recommendations, assigned levels of evidence and strengths of recommendations, and the key updates were integrated into practical treatment algorithms reflecting Taiwan's practice considerations. This updated consensus provides a continuity-based, yet evidence-responsive framework to facilitate the integration of emerging therapies into clinical practice in Taiwan and the Asia-Pacific region.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"29 3","pages":"221-236"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response-Adapted Surgery for Residual Calcifications in HER2-Positive Breast Cancer After Neoadjuvant Chemotherapy.","authors":"Jeong Eon Lee, Cho Eun Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Eun Young Ko, Ji Soo Choi, Eun Sook Ko, Jeongmin Lee, Boo-Kyung Han, Woong Ki Park","doi":"10.4048/jbc.2026.0038","DOIUrl":"10.4048/jbc.2026.0038","url":null,"abstract":"<p><p>The clinical significance of residual mammographic microcalcifications after neoadjuvant systemic therapy in human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer remains unclear. Traditionally, persistent calcifications have prompted wide excisions or mastectomies under the assumption that they indicate residual disease. However, accumulating evidence suggests that calcifications may persist as treatment-related or biologically-attenuated changes, rather than as viable carcinomas, particularly in the era of dual HER2-directed therapy. Recent Korean studies demonstrate that patients with favorable radiologic response who achieve pathologic complete response maintain excellent local control after breast-conserving surgery, even when residual calcifications are present. A large multicenter cohort study reported a 5-year local recurrence-free survival rate of 97.4% and a validated prediction model showed strong discriminatory performance. This Brief Communication synthesizes emerging evidence on the biological basis and clinical implications of residual calcifications after neoadjuvant therapy, with emphasis on recent Korean data. Current evidence supports a response-adapted surgical approach in selected patients, emphasizing clip-guided excision of the invasive index lesion and consistent delivery of whole-breast irradiation rather than routine removal of the entire pretreatment calcification field in patients with HER2+ breast cancer. Prospective validation with a long-term follow-up is warranted to further refine patient selection and confirm the safety of this strategy in clinical practice.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"299-306"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in Identifying Sentinel Lymph Nodes in Early Breast Cancer Patients: Should We Opt for Standard Axillary Lymph Node Dissection?","authors":"Jun Hyung Bang, Seokwon Lee","doi":"10.4048/jbc.2025.0193","DOIUrl":"10.4048/jbc.2025.0193","url":null,"abstract":"<p><strong>Purpose: </strong>Assessing the metastatic status of axillary lymph nodes is critical in breast cancer to determine disease progression and guide treatment. Axillary lymph node dissection (ALND) is performed when sentinel lymph nodes (SLNs) are undetectable; however, this can lead to overtreatment and complications. This study investigated whether limited axillary lymph node dissection (L-ALND) provides outcomes comparable to those of standard axillary lymph node dissection (S-ALND) in patients with early stage breast cancer.</p><p><strong>Methods: </strong>Medical records of 2,461 patients were reviewed, focusing on 304 cases with undetectable SLNs. After excluding those with three or more metastatic nodes, 217 patients with early-stage disease were analyzed. They were classified into L-ALND (≤ 9 nodes removed) and S-ALND (≥ 10 nodes removed) groups.</p><p><strong>Results: </strong>The L-ALND group had a lower local recurrence rate (1.6% vs. 3.4%) and fewer complications than the S-ALND group. Similarly, the five- and ten-year recurrence-free survival rates were higher in the L-ALND group than in the S-ALND group (95.0% vs. 89.1% and 94.2% vs. 49.5%). Factors affecting recurrence included the ALND type (S-ALND vs. L-ALND), type of operation, and tumor subtype. The incidence of lymphedema was also lower in the L-ALND group than in the S-ALND group (4.8% vs. 10.3%).</p><p><strong>Conclusion: </strong>L-ALND offers outcomes comparable to S-ALND in early-stage breast cancer, reducing complications without compromising oncological outcomes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"248-261"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tall Cell Carcinoma With Reversed Polarity of the Breast: A Case Report.","authors":"Yufei Xue, Weiwei Wang, Zhanguo Sun","doi":"10.4048/jbc.2026.0045","DOIUrl":"10.4048/jbc.2026.0045","url":null,"abstract":"<p><p>Tall cell carcinoma with reversed polarity (TCCRP) of the breast is a rare malignant neoplasm that shares morphological similarities with the tall-cell variant of papillary thyroid carcinoma, which may lead to diagnostic confusion. Immunohistochemical and molecular analyses are essential to confirm mammary origin and exclude metastatic thyroid carcinoma. Herein, we report a case of a 62-year-old woman, who was diagnosed with TCCRP based on characteristic histomorphological features and immunohistochemical findings in a breast mass. Despite exhibiting a triple-negative immunophenotype, TCCRP is associated with an indolent clinical course. Accurate diagnosis requires integration of morphological, immunohistochemical, and molecular features, which are critical for appropriate classification and may help support a more conservative management approach.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"307-312"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Performance of International and Korean Genetic Testing Criteria for Hereditary Breast Cancer: A Large-Scale Cohort Analysis of 2,188 Individuals.","authors":"Bom-Yi Lee, Hyun Jeong Lee, Jiyoung Kim, Dongwon Kim, Jiwon Jeong, Kyungah Yoh, Eunyoung Kang, Sung-Won Kim","doi":"10.4048/jbc.2025.0239","DOIUrl":"10.4048/jbc.2025.0239","url":null,"abstract":"<p><strong>Purpose: </strong>International guidelines, including the American Society of Breast Surgeons, American Society of Clinical Oncology-Society of Surgical Oncology (ASCO-SSO), and National Comprehensive Cancer Network (NCCN), have broadened the eligibility for germline testing in breast cancer (BC), whereas the Korean Health Insurance Review and Assessment Service (K-HIRA) criteria remain more restrictive. This study evaluated the prevalence of pathogenic variants (PVs) and compared the diagnostic yield of Korean versus international criteria in a high-risk hereditary BC cohort from a single-institution.</p><p><strong>Methods: </strong>We retrospectively analyzed 2,188 individuals referred for genetic counseling between January 2015 and June 2025. Germline testing included <i>BRCA1/2</i> sequencing, multiplex ligation-dependent probe amplification, and multigene panels. Eligibility was determined according to the ASCO-SSO (Recommendation 1.1), NCCN (v3.2025), and K-HIRA. The prevalence, sensitivity, and number of missed cases of PVs were compared.</p><p><strong>Results: </strong>PVs were identified in 178 (8.1%) patients. Among patients with BC (n = 1,796), 159 carried PVs (8.9%), 131 (82.4%) carried <i>BRCA1/2</i>, and 28 (17.6%) carried non-BRCA genes. Across the frameworks, the prevalence of PV among eligible patients was comparable (ASCO-SSO, 8.7%; NCCN, 9.5%; K-HIRA, 10.2%). The sensitivity differed (NCCN, 96.9%; ASCO-SSO, 92.5%; K-HIRA, 89.3%): the sensitivity of NCCN was significantly higher than that of K-HIRA (<i>p</i> = 0.001), whereas the differences were not significant for NCCN vs. ASCO-SSO (<i>p</i> = 0.071) and ASCO-SSO vs. K-HIRA (<i>p</i> = 0.336). Missed carriers were more frequent under K-HIRA (17/159, 10.7%) than under ASCO-SSO (12/159, 7.5%) and NCCN (5/159, 3.1%), and those missed by K-HIRA often had non-specific family histories (58.8%) or no family history (23.5%).</p><p><strong>Conclusion: </strong>In this cohort, K-HIRA criteria showed lower sensitivity than the international guidelines, leading to missed opportunities for prevention and treatment. Broader eligibility criteria and the integration of multigene testing may improve the detection of hereditary cancer and optimize clinical management in Korea.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"262-276"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"α-Viniferin Induces Intrinsic Apoptosis in Triple-Negative Breast Cancer Cells and Synergizes With SB203580 Independently of p38 Mitogen-Activated Protein Kinase.","authors":"Do-Gyeong Kim, Gyeongmi Kim, Ji Yea Kim, Se-Kyeong Jang, Hyunggee Kim, Hyeon-Ok Jin, Min-Ki Seong, Chan Sub Park, In-Chul Park, Hyun-Ah Kim","doi":"10.4048/jbc.2026.0016","DOIUrl":"10.4048/jbc.2026.0016","url":null,"abstract":"<p><strong>Purpose: </strong>Triple-negative breast cancer (TNBC) is recognized as the most aggressive subtype of breast cancer. Due to the absence of established molecular targets, treatment options remain limited. In this study, we investigated the anticancer effects of α-viniferin in TNBC cells.</p><p><strong>Methods: </strong>The impact of α-viniferin on cell viability was evaluated across several breast cancer cell lines representing different molecular subtypes, as well as in human dermal fibroblasts, using MTT assays. Apoptotic cell death, mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) levels were assessed through flow cytometry. The involvement of signaling pathways was investigated via western blotting and small interfering RNA (siRNA)-mediated knockdown of p38α and p38β.</p><p><strong>Results: </strong>Our findings revealed that α-viniferin induced apoptotic cell death in a time- and dose-dependent manner more effectively in TNBC cells than in other breast cancer subtypes. α-Viniferin triggered intrinsic apoptotic cell death in TNBC cells by downregulating anti-apoptotic Bcl-2 family proteins, disrupting MMP, and cleaving poly(ADP-ribose) polymerase and caspase-3, which is accompanied by increased intracellular ROS levels. Notably, SB203580, a selective p38 inhibitor, synergistically enhanced α-viniferin-induced cytotoxicity. However, this synergistic effect was independent of p38 mitogen-activated protein kinase (MAPK) signaling, as siRNA-mediated knockdown of p38α and p38β did not replicate the observed synergistic cell death in TNBC cells.</p><p><strong>Conclusion: </strong>Collectively, these findings indicate that α-viniferin induces apoptotic cell death in TNBC cells and that SB203580 enhances this cytotoxic effect through a mechanism independent of p38 MAPK signaling, suggesting a potential combination strategy for the treatment of TNBC.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"277-289"},"PeriodicalIF":3.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}